 |
- Last updated refers to the date when our listing for each treatment was last updated.
- ID is our internal ID - starting with VT.
- Min Karnofsky is a general guide to how well you have to function to use this treatment
- For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.
 |
 |
 |
 |
 |
 |
Treatment Name: |
 |
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas |
 |
 |
 |
 |
 |
 |
Keywords: |
 |
Gleevec |
 |
 |
 |
 |
Phase: |
 |
Phase 1 |
 |
 |
 |
 |
 |
 |
Treatment ID#s: |
 |
VT1747
|
 |
 |
 |
 |
Age Group: |
 |
Adult And Pediatric |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
Not Specified |
 |
 |
 |
 |
Conditions: |
 |
Newly Diagnosed: ?
Recurrent: Y
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
11/21/2006 |
 |
 |
 |
 |
Tumor Types: |
 |
Pediatric Brain Tumors |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
|
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy Less-Toxics. |
 |
 |
 |
 |
Contact: |
 |
U. of Texas Southwestern Medical Center at Dallas Elizabeth A. Maher, MD, PhD 5323 Harry Hines Blvd Dallas, TX 75390 Phone:214-645-5000 Click here to send an email Website: www8.utsouthwestern.edu/utsw/cda/dept27827/files/46399.html |
 |
 |
|
|